AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

 AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

Shots:

  • The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries
  •  In Jul’2017, the P-III FLAURA study met its 1EPs of improvement in PFS and the updated results demonstrated improvement in OS with safety & tolerability profile consistent with the previous studies
  • Tagrisso is an irreversible EGFR-TKI targeting both EGFR-sensitizing and EGFR T790M-resistance mutations with clinical activity against CNS metastases and is an approved therapy in 70+ countries for 1L EGFRm advanced NSCLC and in 80+ countries for EGFR T790M mutation-positive advanced NSCLC

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post